XELOX (Capecitabine Plus Oxaliplatin): Active First-Line Therapy for Patients With Metastatic Colorectal Cancer

摘要: Purpose Capecitabine has demonstrated high efficacy as first-line treatment for metastatic colorectal cancer (MCRC). Oxaliplatin shows synergy with fluorouracil (FU), little toxicity overlap. The XELOX regimen (capecitabine plus oxaliplatin), established in a previous dose-finding study, should improve on infused oxaliplatin FU and leucovorin (FOLFOX) regimens. present studies further characterize safety of the regimen. Patients Methods antitumor activity was investigated colon xenograft model. MCRC received 3-week cycles: intravenous 130 mg/m 2 (day 1) followed by oral capecitabine 1,000 twice daily 1, evening, to day 15, morning). Results A preclinical study confirmed that supra-additive oxaliplatin. In clinical 53 96 patients (55%) achieved an objective response, 30 (31%) experienced disease stabilization 3 months following treatment. After 24 months’ minimum follow-up, median time progression (TTP) overall survival were 7.7 19.5 months, respectively. predictable similar FOLFOX4 regimen, except myelosuppression uncommon (grade or 4 neutropenia, 7%). Most adverse events mild moderate, most common being acute sensory neuropathy (85%). Sixty-day, all-cause mortality 2%. Conclusion is highly effective MCRC. Response rates, TTP, are those observed FU/leucovorin/oxaliplatin combinations. provides more convenient likely be preferred both healthcare providers. potential replace FU/LV combination J Clin Oncol 22:2084-2091. © 2004 American Society Clinical Oncology